Authors

Latest:

Dr Doger de Spéville on Key Efficacy Findings From Part C of TACTI-002 in HNSCC

Bernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma.

Jonathan M. Gerber, MD

Jonathan M. Gerber, MD, is a member of the faculty in the Department of Medicine at New York University (NYU) Grossman School of Medicine; as well as the chief clinical officer of the NYU Perlmutter Cancer Center.

Latest:

Dr Gerber on the Benefits of p53 IHC Testing for Identifying TP53-Mutant MDS and AML in Underserved Regions

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Surbhi Sidana, MD

Surbhi Sidana, MD, is an associate professor of medicine and associate director for Clinical Research in the Bone Marrow Transplantation and Cell Therapy Division at Stanford University in California.

Latest:

Dr Sidana on the FDA Approval of Belantamab Mafodotin Plus Vd in R/R Myeloma

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Nikolai Podoltsev, MD, PhD

Nikolai Podoltsev, MD, PhD, is an associate professor of internal medicine (hematology); Duffy Firm Chief for Education, Department of Internal Medicine; associate director, Hematology/Oncology Fellowship Program, Department of Internal Medicine; clinical director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology, Yale Cancer Center.

Latest:

Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

Michelle Chi, MD

Latest:

Assessing Bleeding Disorders: Keys for Hem/Onc Fellows

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

Gregory Peter Kalemkerian, MD

Latest:

Dr Kalemkerian on Unmet Needs With the Use of Chemoimmunotherapy in ES-SCLC

Gregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.

Nelli Bejanyan, MD

Latest:

OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

Kersti Oselin, MD, PhD

Latest:

Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLC

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Lindsay L. Kroener, MD

Latest:

Dr. Kroener on Utilizing Embryo Cryopreservation in Breast Cancer

Lindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.

Kun-Hsing Yu, MD, PhD

Kun-Hsing Yu, MD, PhD, is an associate professor of Biomedical Informatics at Harvard Medical School, an assistant professor of pathology at Brigham and Women's Hospital, and an instructor in epidemiology at Harvard T.H. Chan School of Public Health.

Latest:

The Future of Pathology With AI: Predicting Prognosis and Personalized Treatment

Payal D. Shah

Latest:

Dr. Shah on the Significance of PARP Inhibitors in Ovarian Cancer

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.

Mark Pegram, MD, Stanford Women's Cancer Center

Latest:

Dr. Pegram on the Evolving Treatment Landscape in HER2+ Breast Cancer

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Arvind N. Dasari, MD, MS

Latest:

Dr Dasari on the Evolving Treatment Paradigm in mCRC

Arvind N. Dasari, MD, MS, discusses the roles for the FDA-approved agents fruquintinib and TAS-102 plus bevacizumab in the mCRC treatment paradigm.

Nilo Azad, MD

Latest:

Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.

Dr. Mitesh Borad

Srinivas K. Tantravahi, MBBS, MRCP

Latest:

Dr Tantravahi on the Efficacy of Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Srinivas K. Tantravahi, MBBS, MRCP, discusses the preliminary efficacy of selinexor in combination with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis, as seen in the phase 1 XPORT-MF-034 trial.

Julia E. McGuinness, MD

Latest:

Dr. McGuinness on Mitigating GI Toxicities With PI3K Inhibitors in PI3K-Mutated Breast Cancer

Julia E. McGuinness, MD, discusses combating gastrointestinal toxicities in PI3K-mutated breast cancer.

Caron A. Jacobson, MD, Dana-Farber Cancer Institute

Latest:

Novel Therapies for R/R Follicular Lymphoma

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

John Henson, MD, Augusta University

Latest:

Operational Processes and Challenges

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.

Mellisa Johnson, MD

Latest:

Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase 2 Ideate-Lung01 Study